ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: 1597 • ACR Convergence 2020

    Use of a Clinical Dashboard Improves the Documentation of Disease Severity Scores and May Facilitate the Implementation of Treat to Target Therapy

    Taylor Nelson1, Gary Kunkel2 and Grant Cannon2, 1University of Utah, Salt Lake City, 2Salt Lake City VA Medical Center and University of Utah, Salt Lake City

    Background/Purpose: Rheumatoid Arthritis (RA) management guidelines recommend the collection of Disease Activity Measures (DAMs) to direct therapy as a component of a “treat-to-target” (T2T) strategy. …
  • Abstract Number: 1760 • ACR Convergence 2020

    The Association Between the Risk of Venous Thromboembolism and Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Observational Study

    Masaru Yoshimura1, Yuichiro Fujieda2, Michihito Kono2, Masaru Kato2, Kenji Oku2, Olga Amengual2 and Tatsuya Atsumi3, 1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 2Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, 3Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is an immune-mediated synovial disease with chronic inflammation. Systemic inflammation is considered one of risk factors for venous thromboembolism (VTE), which…
  • Abstract Number: 1887 • ACR Convergence 2020

    Spinal Mobility and Function: How Closely Do They Associate in Axial Spondyloarthropathy?

    Sinead Maguire1, Phil Gallagher2 and Finbar O'Shea1, 1St James' Hospital, Dublin, Ireland, 2St Vincents University Hospital, UCD, Dublin, Ireland

    Background/Purpose: Axial spondyloarthropathy (axSpA) is a form of inflammatory arthritis affecting the axial skeleton. Persistent disease activity can result in restricted spinal mobility over time,…
  • Abstract Number: 033 • 2020 Pediatric Rheumatology Symposium

    Parental Adverse Childhood Experience (ACE) Exposure Is Predictive of Active Lupus in Pediatric Patients

    Michael Nelson1, Nancy Correa 2, Ashley Butler 1, Marietta De Guzman 3, Bethanie Van Horne 1 and Christopher Greeley 1, 1Baylor College of Medicine, Houston, 2Texas Children's Hospital, Houston, 3Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas

    Background/Purpose: Adverse Childhood Experiences (ACEs) have been recognized for more than two decades as risk factors for poor health outcomes in adults. Nevertheless, the impact…
  • Abstract Number: 071 • 2020 Pediatric Rheumatology Symposium

    Patient Reported Outcomes and Resilience in Pediatric Systemic Lupus Erythematosus

    Lauren Ambler1, Rula Issa 2, Stephanie Pan 2 and Rebecca Trachtman 2, 1Mount Sinai Hospital, New York, 2Icahn School of Medicine at Mount Sinai, New York

    Background/Purpose: It has been established that pediatric Systemic Lupus Erythematous (pSLE) is associated with lower health-related quality of life (HRQOL); however, there are few studies…
  • Abstract Number: 078 • 2020 Pediatric Rheumatology Symposium

    Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma

    Suzanne Li1, Mara Becker 2, Sandy Hong 3, Polly Ferguson 4, Themba Nyrienda 5, Tracy Andrews 6, Katie Stewart 7, C. Egla Rabinovich 8, Robert Fuhlbrigge 9, Thomas Mason 10, Elena Pope 11, Maria Ibarra 12, Fatma Dedeoglu 13, Gloria Higgins 14, Ronald Laxer 15, Marilynn Punaro 16 and Kathryn Torok 17 for the CARRA investigators, 1Joseph M. Sanzari Children's Hospital Hackensack Meridian Health, Hackensack, 2Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, 3University of Iowa Stead Family Children's Hospital, Iowa City, 4University of Iowa Carver College of Medicine, Iowa City, 5Hackensack Univesity Medical Center, Hackensack, 6Rutgers University, Newark, 7UT Southwestern, Dallas, 8Duke University Hospital, Durham, 9University of Colorado, Aurora, 10Rochester, 11Hospital For Sick Kids, Toronto, Canada, 12Children's Mercy Kansas City, Kansas City, 13Boston Children's Hospital, Boston, 14Nationwide Childrens Hospital/ The Ohio State University, Columbus, 15The Hospital for Sick Children and University of Toronto, Toronto, Canada, 16Dallas, Texas, 17Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh

    Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease. Treatment is directed towards controlling disease activity to minimize risk for functional impairment…
  • Abstract Number: 128 • 2020 Pediatric Rheumatology Symposium

    Predictors of Moderate/High Disease Activity in Childhood-Onset Systemic Lupus Erythematosus

    Emily Smitherman1, Rouba Chahine 1, Timothy Beukelman 1, Andrea Knight 2, AKM Fazlur Rahman 1, Mary Beth Son 3, Jeffrey R Curtis 4 and Aimee Hersh 5 for the CARRA investigators, 1University of Alabama at Birmingham, Birmingham, 2SickKids Research Institute, Toronto, Canada, 3Boston Children's Hospital, Boston, Massachusetts, 4University of Alabama at Birmingham, Hoover, 5University of Utah Primary Children's Hospital, Salt Lake City

    Background/Purpose: Substantial risk of early morbidity and mortality exists for patients with childhood-onset systemic lupus erythematosus (cSLE), but there are limited studies identifying predictors of…
  • Abstract Number: 139 • 2020 Pediatric Rheumatology Symposium

    Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study

    Mia Glerup1, Ellen D Arnstad 2, Veronika Rypdal 3, Suvi Peltoniemi 4, Kristiina Aalto 5, Marite Rygg 6, Susan Nielsen 7, Anders Fasth 8, Lillemor Berntson 9, Ellen Nordal 3 and Troels Herlin 10, 1Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, 2Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, and Department of Pediatrics, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Tromheim, Norway, 3Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, 4Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., Helsinki, Finland, 5Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, 6Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, 7Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhagen, Denmark, 8Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, 9Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, 10Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark

    Background/Purpose: Previously, we showed that ILAR JIA categories defined at disease onset change considerably during the first 8 years of disease course. Whether achieved remission…
  • Abstract Number: L17 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial

    Eric Morand1, Richard Furie 2, Yoshiya Tanaka 3, Ian Bruce 4, Anca Askanase 5, Christophe Richez 6, Sang-Cheol Bae 7, Philip Brohawn 8, Lilia Pineda 9, Anna Berglind 10 and Raj Tummala 9, 1Monash University, Melbourne, Victoria, Australia, 2Zucker School of Medicine at Hofstra/Northwell, New York, 3University of Occupational and Environmental Health, Kitakyushu, Japan, 4University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, 5Columbia University, New York, 6CHU de Bordeaux-GH Pellegrin, Bordeaux, France, 7Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 8Former employee of AstraZeneca, Gaithersburg, Maryland, 9AstraZeneca, Gaithersburg, Maryland, 10AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…
  • Abstract Number: 1193 • 2019 ACR/ARP Annual Meeting

    EMR-integrated Disease Activity Calculators Improve Treatment to Target in Rheumatoid Arthritis

    Gabrielle Barbera1, Jasleen Kahlon 2, Manank Patel 3, Scott Pompa 4 and Arundathi Jayatilleke 1, 1Drexel, Philadelphia, PA, 2Hahnemann, Philadelphia, PA, 3Rutgers, New Brunswick, NJ, 4Dartmouth, Lebanon, NH

    Background/Purpose: Undertreatment of RA can lead to cumulative joint damage as well as negatively impact emotional health. Recent evidence favors a treat-to-target strategy to achieve…
  • Abstract Number: 2443 • 2019 ACR/ARP Annual Meeting

    A Gender-based Analysis of Disease Activity and Its Relationship with Anxiety, Depression, Fatigue, and Fibromyalgia in Psoriatic Arthritis

    Mehmet Tuncay Duruoz1, Halise Hande Gezer 2, Kemal Nas 3, Erkan Kilic 4, Betul Sargin 5, Sevtap Acer Kasman 1, Hakan Alkan 6, Nilay Sahin 7, Gizem Cengiz 8, Nihan Cuzdan 9, Ilknur Albayrak Gezer 10, Dilek Keskin 11, Cevriye Mulkoglu 12, Hatice Resorlu 13, Şebnem Ataman 14, Ajda Bal 15, Okan Kucukakkas 16, Ozan Volkan Yurdakul 16, Meltem Alkan Melikoglu 17, Yildiray Aydin 3, Fikriye Figen Ayhan 18, Hatice Bodur 19, Mustafa Calis 8, Erhan Capkin 20, Gul Devrimsel 21, Kevser Gök 22, Sami Hizmetli 23, Ayhan Kamanli 3, Yasar Keskin 16, Hilal Kocabas 24, Oznur Kutluk 25, Nesrin Sen 26, Omer Faruk Sendur 27, Ibrahim Tekeoglu 3, Sena Tolu 28, Murat Toprak 29 and Tiraje Tuncer 25, 1Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Turkey, 2Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Istanbul, Turkey, 3Sakarya University School of Medicine, PMR Department, Rheumatology and Immunology Division, Sakarya, Turkey, 4Afyonkarahisar State Hospital, Afyonkarahisar, Turkey, 5Adnan Menderes University School of Medicine, PMR Department, Rheumatology Division, Aydın, Turkey, 6Pamukkale University School of Medicine, PMR Department, Rheumatology Division, Denizli, Turkey, 7Balıkesir University School of Medicine, PMR Department, Balıkesir, Turkey, 8Erciyes University School of Medicine, PMR Department, Rheumatology Division, Kayseri, Turkey, 9Şanlıurfa Training and Research Hospital, Rheumatology Clinic, Şanlıurfa, Turkey, 10Selçuk University School of Medicine, PMR Department, Konya, Turkey, 11Kırıkkale University School of Medicine, PMR Department, Kırıkkale, Turkey, 12Ankara Training and Research Hospital, PMR Clinic, Ankara, Turkey, 13Çanakkale Onsekiz Mart University School of Medicine, PMR Department, Çanakkale, Turkey, 14Ankara University School of Medicine, Physical Medicine and Rehabilitation, Rheumatology Department, Ankara, Ankara, Turkey, 15Dışkapı Yıldırım Beyazıt Training and Research Hospital, PMR Clinic, Ankara, Turkey, 16Bezmialem Vakıf University School of Medicine, PMR Department, İstanbul, Turkey, 17Atatürk University School of Medicine, PMR Department, Rheumatology Division, Erzurum, Turkey, 18Uşak University School of Health Sciences, PMR Department, Uşak, Turkey, 19Yıldırım Beyazıt University School of Medicine, PMR Department, Ankara, Turkey, 20Karadeniz Teknik University School of Medicine, PMR Department, Trabzon, Turkey, 21Recep Tayyip Erdoğan University School of Medicine, PMR Department, Riza, Turkey, 22Numune Training and Research Hospital, Rheumatology Clinic, Ankara, Turkey, 23Cumhuriyet University School of Medicine, PMR Department, Rheumatology Division, Sivas, Turkey, 24Necmettin Erbakan University Meram School of Medicine, PMR Department, Rheumatology Division, Konya, Turkey, 25Akdeniz University School of Medicine, PMR Department, Rheumatology Division, Antalya, Turkey, 26Kartal Dr. Lütfi Kırdar Training and Research Hospital, Rheumatology Clinic, İstanbul, Turkey, 27Adnan Menderes University School of Medicine, PMR Department, Aydın, Turkey, 28Medipol University School of Medicine, PMR Department, İstanbul, Turkey, 29Yüzüncü Yıl University School of Medicine, PMR Department, Van, Turkey

    Background/Purpose: This study sought to compare the disease activity and its relationship with anxiety, depression, fatigue, and fibromyalgia of patients with psoriatic arthritis (PsA) between…
  • Abstract Number: 36 • 2019 ACR/ARP Annual Meeting

    Discovery, Verification and Validation of Rheumatoid Arthritis Activity Monitoring Biomarkers

    Lucía González-Rodríguez1, Valentina Calamia 1, Rocío Paz-González 1, Patricia Fernández-Puente 1, Cristina Ruiz-Romero 1, Antonio Julià 2, Antonio Fernández-Nebro 3, Jesús Tornero 4, Sara Marsal 5 and Francisco J. Blanco 6, 1Proteomics Group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña,15006 A Coruña-Spain, A Coruña, Galicia, Spain, 2Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, 3UGC Reumatología, Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Spain., Málaga, Andalucia, Spain, 4Hospital Universitario Guadalajara, Guadalajara, Spain., Guadalajara, Castilla-La Mancha, Spain, 5Vall d’Hebron Hospital, Barcelona, Catalonia, Spain, 6Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is a long-lasting inflammatory autoimmune disorder that ultimately leads to the destruction of joint architecture. The activity of this disease is…
  • Abstract Number: 1355 • 2019 ACR/ARP Annual Meeting

    A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures

    Grant Cannon1, Wei Chen 1, JIncheng Shen 2, Neil Accortt 3, David Collier 4 and Brian Sauer 1, 1Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, 2Univeristy of Utah, Salt Lake City, UT, 3Amgen, Thousand Oaks, CA, 4Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Despite ACR recommendations to initiate a major therapeutic change (MTC) in rheumatoid arthritis (RA) patients with moderate/severe disease activity, our recent work has shown…
  • Abstract Number: 2483 • 2019 ACR/ARP Annual Meeting

    Comparison Between Composite Activity Indices to Assess Clinical Response to Biological Therapy in Patients with Psoriatic Arthritis

    Diego Benavent1, Chamaida Plasencia 2, Victoria Navarro-Compán 3, Diana Peiteado 4, Laura Nuño 5, Irene Monjo 6, Elisa Fernández 7 and Alejandro Balsa 2, 1Hospital Universitario La Paz, Madrid, Spain, 2Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, 3University Hospital La Paz, IdiPaz, Madrid, Spain, 4Hospital Universitario La Paz, Madrid, 5Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, MADRID, Spain, 6FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, 7Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain

    Background/Purpose: Assessment of the disease in psoriatic arthritis (PsA) remains a clinical challenge. Hence, there is no agreement on which index best correlates with the…
  • Abstract Number: 46 • 2019 ACR/ARP Annual Meeting

    Key Inflammatory Biomarkers at Baseline Are Associated with Filgotinib Response at Week 12 in Rheumatoid Arthritis Patients with Inadequate Response or Intolerance to Biologic DMARDs

    Peter Taylor1, Emon Elboudwarej 2, Bryan Downie 3, Rachael Hawtin 2, Jinfeng Liu 2 and Amer M. Mirza 2, 1University of Oxford, Oxford, United Kingdom, 2Gilead Sciences, Inc., Foster City, CA, 3Gilead Sciences, Inc., Foster Citty, CA

    Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in Phase 3 studies of active RA in patients (pts) with inadequate…
  • « Previous Page
  • 1
  • …
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
  • 112
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology